Responses to TLK199
Hi All,
Now researchers report that underexpression of a special gene set - the JNK gene set - perhaps may identify patients likely to respond to Ezatiostat (TLK199). C-Jun NH2-terminal kinase (JNK) is implicated in transformation to cancer. The abstract is complicated – you will find the important info in this sentence: The expression data confirms that patients whose pre-therapy marrow shows under-expression of the JNK gene set are precisely those who benefit from this drug therapy and those patients who already over-express these genes are unlikely to respond. http://ash.confex.com/ash/2011/webpr...aper37656.html This kind of research is very important and we hope they at last will find out the best treatment for all MDS patients. Patients with the 5q- will often respond to Revlimid, patients with lower DNA methylation of the WT1 gene will perhaps have a better response to Vidaza and patients with underexpression of the JNK gene set will eventually respond to Ezatiostat. Kind regards Birgitta-A |
All times are GMT -4. The time now is 10:16 AM. |
Powered by vBulletin® Version 3.6.7
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.
Forum sites may contain non-authoritative and unverified information.
Medical decisions should be made in consultation with qualified medical professionals.
Site contents exclusive of member posts Copyright © 2006-2020 Marrowforums.org